N-ferrocenylmethyl-Derivatives As Spike Glycoprotein Inhibitors Of SARS-CoV-2 Using In Silico Approaches

12 May 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Background and Objectives: By the end of 2019, a novel human coronavirus outbreak started in Wuhan and spread to the world becoming a global pandemic, patients were diagnosed with severe respiratory syndrome. Studies have shown that SARS-CoV2 interact with angiotensin-converting enzyme 2 (ACE2), its host cell receptor, by its Spike Glycoprotein. The aim of this study is to prevent this interaction by inhibiting Spike glycoprotein. Materials and Methods: The interaction of the Spike Glycoprotein of SARS-COV-2 extracted from protein data bank (PDB Code: 6VSB and 6LZG) with 10 different ferrocene derivatives ligands were investigated by performing docking studies using Autodock Tools 4.2. software. Results: The obtained results showed that N-ferrocenyl-methyl-3-nitroaniline was the best inhibitor ligand interacted with both proteins of coronavirus with the free binding energy equal to -5.38 and -6.65 Kcal/mol for 6VSB and 6LZG respectively with binding constant values equal to 8.7 × 103 and 72.72× 103respectively. Calculations revealed that the dominated mode of interaction for all the studied ligands with COVID-19 was the electrostatic mode via at least one H-bond and more than two hydrophobic Pi-Alkyl Bonds. Conclusion: Generally, the results indicated the existence of strong interactions between ligands and spike glycoprotein which prevent the virus to interact to ACE2 receptors.

Keywords

SARS-CoV-2
Docking Studies
docking
ferrocenyl-methyl
spike glycoprotein

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.